NCT06264427 Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland
| NCT ID | NCT06264427 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Steno Diabetes Center Greenland |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-07-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2022-07-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: * Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: * Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes and/or morbid obesity (BMI \>40) * Over 18 years old Exclusion Criteria: * Does not speak either English, Danish or Greenlandic
Contact & Investigator
Marit Eika Jørgensen, Md. Phd
PRINCIPAL INVESTIGATOR
Steno Diabetes Center Greenland
Frequently Asked Questions
Who can join the NCT06264427 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06264427 currently recruiting?
Yes, NCT06264427 is actively recruiting participants. Contact the research team at MMSN@peqqik.gl for enrollment information.
Where is the NCT06264427 trial being conducted?
This trial is being conducted at Nuuk, Greenland.
Who is sponsoring the NCT06264427 clinical trial?
NCT06264427 is sponsored by Steno Diabetes Center Greenland. The principal investigator is Marit Eika Jørgensen, Md. Phd at Steno Diabetes Center Greenland. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.